The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Communications and UpdatesFull Access

Trainees and Collaborations With Industry

To the Editor: As a recent graduate of residency and fellowship in psychiatry, I read the article by David B. Merrill, M.D., et al. (1) with great interest. I struggled to define my relationship with the pharmaceutical industry throughout residency, as did most of my classmates in our program at Cambridge Hospital. I have not chosen a research-focused career, and I have great admiration for those who struggle to find funding and collaborate with industry. However, I do have one question that I was unable to answer from reading the article: What ultimately happened to the authors' finding that the study drug, aripiprazole, and control drug, haloperidol, showed no significant difference in efficacy? They refer to a study, but there is no corresponding publication citation.

Northampton, Mass.

accepted for publication in June 2010.

The author reports no financial relationships with commercial interests.

Reference

1. Merrill DB , Girgis RR , Bickford LC , Vorel SR , Lieberman JA: Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry 2010; 167:381–386LinkGoogle Scholar